MINI FUTURE LONG - ROCHE GS Share Price

Certificat

DE000MD18S84

Market Closed - Börse Stuttgart 12:01:51 08/06/2024 am IST
5.01 EUR +6.60% Intraday chart for MINI FUTURE LONG - ROCHE GS
Current month+29.79%
1 month+67.00%
Date Price Change
07/24/07 5.01 +6.60%
06/24/06 4.7 +4.91%
05/24/05 4.48 +4.19%
04/24/04 4.3 +5.91%
03/24/03 4.06 +5.18%

Delayed Quote Börse Stuttgart

Last update June 08, 2024 at 12:01 am IST

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MD18S8
ISINDE000MD18S84
Date issued 18/01/2022
Strike 192.6 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 16.94
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 21.28
Lowest since issue 2.32

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
242.6 CHF
Average target price
277.5 CHF
Spread / Average Target
+14.40%
Consensus